Numelvi®
NUMELVI is a once-daily tablet, first-line treatment, and is the only second-generation Janus kinase (JAK) inhibitor indicated for the treatment of pruritus associated with allergic dermatitis including atopic dermatitis and treatment of clinical manifestations of atopic dermatitis in dogs.
Numelvi – the next generation of itch relief – is a new product for managing canine allergic dermatitis, offering selectivity, safety, and simplicity.
Active Ingredients
Numelvi contains Atinvicitinib.
Indications
For the treatment of pruritus associated with allergic dermatitis including atopic dermatitis in dogs.
For the treatment of inflammation and clinical manifestations of atopic dermatitis in dogs.
Dosage
Numelvi should be administered once daily at or around mealtime at a dose of 0.8 – 1.2 mg/kg of Atinvicitinib in accordance with the following table:
Numelvi, ACVM No: A012149, is AVAILABLE ONLY UNDER VETERINARY AUTHORISATION
Additional Information
Pack Sizes:
Available in 4 tablet strengths for simple dosing: 4.8mg Atinvicitinib Small – 30 tablet bottles, and all other products in 90 tablet bottles: 7.2mg Atinvicitinib Medium, 21.6mg Atinvicitinib Large and 31.6mg Atinvicitinib Extra Large.